Obredon is a drug owned by Sovereign Pharmaceuticals Llc. It is protected by 3 US drug patents filed from 2017 to 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 13, 2035. Details of Obredon's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9549907 | Immediate release oral guaifenesin solution |
Nov, 2035
(10 years from now) | Active |
| US10105324 | Immediate release oral guaifenesin solution |
Nov, 2035
(10 years from now) | Active |
| US9808431 | Immediate release oral guaifenesin solution |
Nov, 2035
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Obredon's patents.
Latest Legal Activities on Obredon's Patents
Given below is the list of recent legal activities going on the following patents of Obredon.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9549907 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 May, 2024 | US9549907 |
| Email Notification Critical | 03 Aug, 2022 | US10105324 |
| Email Notification Critical | 03 Aug, 2022 | US9549907 |
| Change in Power of Attorney (May Include Associate POA) Critical | 03 Aug, 2022 | US9549907 |
| Change in Power of Attorney (May Include Associate POA) Critical | 03 Aug, 2022 | US10105324 |
| Change in Power of Attorney (May Include Associate POA) Critical | 03 Aug, 2022 | US9808431 |
| Email Notification Critical | 03 Aug, 2022 | US9808431 |
| Correspondence Address Change Critical | 01 Aug, 2022 | US9808431 |
| Correspondence Address Change Critical | 01 Aug, 2022 | US10105324 |
US patents provide insights into the exclusivity only within the United States, but Obredon is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Obredon's family patents as well as insights into ongoing legal events on those patents.
Obredon's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Obredon's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 13, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Obredon Generics:
There are no approved generic versions for Obredon as of now.
About Obredon
Obredon is a drug owned by Sovereign Pharmaceuticals Llc. It is used for increasing the bioavailability of guaifenesin. Obredon uses Guaifenesin; Hydrocodone Bitartrate as an active ingredient. Obredon was launched by Sovereign Pharms in 2014.
Approval Date:
Obredon was approved by FDA for market use on 14 November, 2014.
Active Ingredient:
Obredon uses Guaifenesin; Hydrocodone Bitartrate as the active ingredient. Check out other Drugs and Companies using Guaifenesin; Hydrocodone Bitartrate ingredient
Treatment:
Obredon is used for increasing the bioavailability of guaifenesin.
Dosage:
Obredon is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG/5ML;2.5MG/5ML | SOLUTION | Discontinued | ORAL |